As of 2025-12-21, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (11.64) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.35 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -367.7%.
The range of the Relative Valuation is (8.53) - (12.32) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.2x - 16.1x | 13.9x |
| Forward P/E multiples | 11.1x - 18.6x | 16.5x |
| Fair Price | (8.53) - (12.32) | (11.64) |
| Upside | -296.2% - -383.2% | -367.7% |
| Date | P/E |
| 2025-12-19 | -5.68 |
| 2025-12-18 | -5.42 |
| 2025-12-17 | -5.23 |
| 2025-12-16 | -5.87 |
| 2025-12-15 | -5.69 |
| 2025-12-12 | -5.30 |
| 2025-12-11 | -5.47 |
| 2025-12-10 | -5.77 |
| 2025-12-09 | -5.40 |
| 2025-12-08 | -5.44 |
| 2025-12-05 | -5.53 |
| 2025-12-04 | -5.22 |
| 2025-12-03 | -5.30 |
| 2025-12-02 | -5.27 |
| 2025-12-01 | -5.77 |
| 2025-11-28 | -5.89 |
| 2025-11-26 | -5.47 |
| 2025-11-25 | -5.56 |
| 2025-11-24 | -5.61 |
| 2025-11-21 | -5.57 |
| 2025-11-20 | -5.64 |
| 2025-11-19 | -5.46 |
| 2025-11-18 | -5.57 |
| 2025-11-17 | -5.18 |
| 2025-11-14 | -5.16 |
| 2025-11-13 | -5.06 |
| 2025-11-12 | -5.10 |
| 2025-11-11 | -4.29 |
| 2025-11-10 | -3.93 |
| 2025-11-07 | -3.46 |
| 2025-11-06 | -3.41 |
| 2025-11-05 | -3.28 |
| 2025-11-04 | -3.62 |
| 2025-11-03 | -2.87 |
| 2025-10-31 | -2.95 |
| 2025-10-30 | -3.03 |
| 2025-10-29 | -3.20 |
| 2025-10-28 | -3.20 |
| 2025-10-27 | -3.04 |
| 2025-10-24 | -2.74 |
| 2025-10-23 | -2.88 |
| 2025-10-22 | -2.79 |
| 2025-10-21 | -2.92 |
| 2025-10-20 | -2.95 |
| 2025-10-17 | -2.62 |
| 2025-10-16 | -2.62 |
| 2025-10-15 | -2.70 |
| 2025-10-14 | -2.52 |
| 2025-10-13 | -2.64 |
| 2025-10-10 | -2.66 |